BIOMARIN PHARMACEUTICAL INC Accrued Royalties, Current
BIOMARIN PHARMACEUTICAL INC (BMRN) had Accrued Royalties, Current of $15.50 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccruedRoyaltiesCurrent · last filed 2026-08-06
- 2026-06-30: Accrued Royalties, Current $15.50M.
- 2026-03-31: Accrued Royalties, Current $6.66M.
- 2025-12-31: Accrued Royalties, Current $7.97M.
- 2025-09-30: Accrued Royalties, Current $6.95M.
| Period end | Accrued Royalties, Current | Accrued Royalties, Current as first filed |
|---|---|---|
| 2026-06-30 | $15.50M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $6.66M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $7.97M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $6.95M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $8.02M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $7.86M 10-Q · filed 2025-05-02 | |
| 2024-12-31 | $7.92M 10-K · filed 2026-02-26 | $13.06M 10-K · filed 2025-02-24 |
| 2024-09-30 | $7.49M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $7.67M 10-Q · filed 2024-08-05 | |
| 2024-03-31 | $10.19M 10-Q · filed 2024-04-26 | |
| 2023-12-31 | $33.85M 10-K · filed 2025-02-24 | $14.30M 10-K · filed 2024-02-26 |
| 2023-09-30 | $12.29M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $13.36M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $14.80M 10-Q · filed 2023-04-28 | |
| 2022-12-31 | $13.31M 10-K · filed 2024-02-26 | |
| 2022-09-30 | $14.49M 10-Q · filed 2022-10-28 | |
| 2022-06-30 | $15.62M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $16.03M 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $15.21M 10-K · filed 2023-02-27 | |
| 2021-09-30 | $14.51M 10-Q · filed 2021-10-29 | |
| 2021-06-30 | $17.20M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $18.27M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $17.16M 10-K · filed 2022-02-25 | |
| 2020-09-30 | $20.43M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $20.69M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $20.33M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $30.80M 10-K · filed 2021-02-26 | |
| 2019-09-30 | $27.88M 10-Q/A · filed 2019-11-04 | |
| 2019-06-30 | $23.06M 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $19.22M 10-Q · filed 2019-04-29 | |
| 2018-12-31 | $19.98M 10-K · filed 2020-02-27 | |
| 2018-09-30 | $19.25M 10-Q · filed 2018-10-26 | |
| 2018-06-30 | $18.62M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $16.50M 10-Q · filed 2018-04-27 | |
| 2017-12-31 | $18.82M 10-K · filed 2019-02-28 | |
| 2017-09-30 | $16.42M 10-Q · filed 2017-10-31 | |
| 2017-06-30 | $15.54M 10-Q · filed 2017-08-02 | |
| 2017-03-31 | $14.11M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $15.15M 10-K · filed 2018-02-26 | |
| 2016-09-30 | $14.18M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $14.70M 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $10.79M 10-Q · filed 2016-05-02 | |
| 2015-12-31 | $10.41M 10-K · filed 2017-02-27 | |
| 2015-09-30 | $9.89M 10-Q · filed 2015-11-02 | |
| 2015-06-30 | $9.52M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $7.21M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $9.05M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $7.57M 10-Q · filed 2014-10-28 | |
| 2014-06-30 | $6.42M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $4.67M 10-Q · filed 2014-05-02 | |
| 2013-12-31 | $5.83M 10-K · filed 2015-03-02 | |
| 2013-09-30 | $5.28M 10-Q · filed 2013-10-28 | |
| 2013-06-30 | $4.50M 10-Q · filed 2013-07-29 | |
| 2013-03-31 | $3.87M 10-Q · filed 2013-04-29 | |
| 2012-12-31 | $4.99M 10-K · filed 2014-02-26 | |
| 2012-09-30 | $4.44M 10-Q · filed 2012-10-29 | |
| 2012-06-30 | $3.89M 10-Q · filed 2012-08-02 | |
| 2012-03-31 | $3.18M 10-Q · filed 2012-04-30 | |
| 2011-12-31 | $5.87M 10-K · filed 2013-02-26 | |
| 2011-09-30 | $6.48M 10-Q · filed 2011-10-31 | |
| 2011-06-30 | $6.39M 10-Q · filed 2011-08-01 | |
| 2010-12-31 | $5.36M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |